Onchocerciasis: Target product profiles of in vitro diagnostics to support onchocerciasis elimination mapping and mass drug administration stopping decisions
Table 5
Effect of specificity on the Type II error of a 30-cluster survey, where treatment decisions are based on the average prevalence of the entire survey area.
No sensitivity assumptions were made. The critical cutoff was ≥ 19 positive tests out of a sample size of 3000. The calculations were made for a true prevalence of 0%. At least 99.6% specificity is required to have a Type II error of < 10%.